How Masteron Affects Haematocrit

Drostanolone is 2-alpha-methyl dihydrotestosterone. The common assumption is that because masteron cannot aromatise, it should be gentle on blood counts. The evidence points the other way, because erythropoiesis does not run through oestrogen.

The pathway is androgen-driven, not oestrogen-driven:

• Aromatase-deficient men, who make almost no oestradiol, still raised haemoglobin and haematocrit when given testosterone (Rochira 2009, PMID 19159688). Oestrogen is not required for the effect.
• In a randomised trial, blocking conversion of testosterone to DHT with dutasteride did not change the haematocrit rise on testosterone (Bhasin 2012, PMID 22396515). That means the rise is not dependent on DHT specifically either; it comes from androgen receptor signalling broadly.
• Testosterone raises erythropoietin and suppresses hepcidin, which frees iron for haemoglobin synthesis (Bachman 2014, PMID 24158761).

What the DHT data shows:

• Transdermal DHT gel for 6 months raised haematocrit from 43.5% to 45.8% and haemoglobin from 146.0 to 154.8 g/L in older men (Kunelius 2002, PMID 11932266).
• In a 24 month DHT gel trial, haemoglobin rose about 7% and 8 men in the DHT group (of 114 randomised) were withdrawn for high haematocrit (Idan 2010, PMID 21079217).
• In mice, DHT showed greater erythroid activity than testosterone (McManus 2020, PMID 32311143), though mouse data is only suggestive for humans.

Drostanolone is a DHT derivative that binds the androgen receptor and does not aromatise, so the most reasonable inference is that it acts through the same androgen receptor, EPO and hepcidin route as DHT. That is an inference. No controlled trial of drostanolone on haematocrit in healthy men exists, and forum reports of haematocrit on masteron are almost always confounded by the testosterone it is stacked with.

Masteron added to a testosterone base (the usual protocol):

• Haematocrit is driven mainly by the testosterone dose (it rises with dose, and more so in older men, Coviello 2008, PMID 18160461). Masteron adds to the total androgen load, so expect it to push you somewhat further along the same curve rather than to behave as a separate effect.
• The size of the added rise has not been measured. The DHT gel trials (roughly 2 to 3 percentage points over 6 months at physiological-range exposure) are the closest human reference, and cycle doses of 300 to 500 mg/week are well above that.
• The rise builds over weeks; the first meaningful change usually shows at the 6 to 8 week bloods.

Masteron alone: no data. Any rise would reflect androgen receptor activation and dose.

After stopping: haematocrit falls back over weeks to a few months as older red cells turn over. Propionate clears faster than enanthate, so the decline starts sooner with propionate.

Who is more exposed: higher baseline haematocrit, older age, sleep apnoea, smoking, dehydration, and stacking with other erythropoietic compounds. Every one of these compounds the androgen effect.

Baseline: full blood count before starting, with haemoglobin and haematocrit. A baseline above about 47% means you have less headroom before the 54% line.

On cycle: recheck at 6 to 8 weeks, then every 8 to 12 weeks for as long as you stay on. If masteron is added to an existing protocol, treat the addition like a dose increase and recheck at 6 to 8 weeks.

Threshold: 54% is the Endocrine Society level at which testosterone therapy should be stopped or withheld until it falls. Staying comfortably below it, rather than reacting once you cross it, is the goal.

Sample properly: draw at a consistent time, hydrated, and not straight after a hard session or a dehydrating cut. Peak week water and sodium manipulation can produce a misleading haematocrit.

Read the trend: a rise of more than about 2 percentage points between checks is worth acting on early, even if you are still under the threshold.

If haematocrit is creeping up (roughly 50 to 53%):

• Recheck sooner, in 3 to 4 weeks
• Look at the whole stack, since masteron is rarely the only contributor
• Review hydration, sleep apnoea symptoms, smoking and any other erythropoietic compounds
• Consider trimming the total androgen load before it becomes a phlebotomy problem

If haematocrit reaches 54% or higher:

• This is a stop-or-reduce signal, not something to push through
• Reduce or remove the dose driving it; therapeutic phlebotomy or blood donation lowers the number in the short term but does not remove the cause
• Discuss with a doctor, particularly if you have symptoms such as headaches, visual disturbance, or a flushed appearance

Do not assume masteron is the safe compound in the stack for blood counts. Being non-aromatising is a statement about oestrogen, which is not the mechanism here.

Further reading: How to lower haematocrit on TRT without blood donation; Does Masteron Lower Estrogen? explains why the non-aromatising label does not make it neutral elsewhere; TRT and hair loss: the DHT question covers the other DHT-related trade-off.